P2Y 2 receptor agonists, denufosol (OLIYNYK et al., 2010), were promising for their ability to activate alternative chloride secretion pathways, but both of these agonists have not been pursued further due to not meeting primary study goals of improving FEV 1 (Ratjen et al., 2012) and having a narrow effective concentration range, respectively (OLIYNYK et al., 2010)
For example, if you have a 15mg vial (15,000mcg) and your protocol calls for a 2,500mcg dose, the total doses is 15,000 / 2,500 = 6 doses
Our team will walk you through the process during your visit and provide thorough education so you feel completely confident whether you are self-administering or coming in for assisted sessions
GLP3, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: A randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA